Botanix Quarterly Activities Report and Appendix 4C Q3 FY26
Filed with ASX · · 13 pages · English
Summary by 6ix AI
Despite a temporary decline in gross-to-net yield due to an annual deductible reset, total prescriptions shipped for Sofdra increased, reaching an all-time high in March. The company is optimistic about continuing sales momentum and has established a term sheet agreement with an alternate API supplier to enhance its supply chain. Overall, Botanix is focused on executing its strategic growth initiatives and expanding its product offerings through its Fulfilment Platform.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings CallBotanix Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Botanix Pharmaceuticals
- Botanix reaches term sheet agreement with 2nd API supplier
- Successful renegotiation of API supply agreement
- S&P DJI Announces March 2026 Quarterly Rebalance
- Appendix 4D and Half Year Report
- Botanix Receives Capital Raise Commitments of A$45 Million
Later from Botanix Pharmaceuticals
- Intention to Grant a European patent on Sofdra applicator
- Notice of Allowance for US patent on Sofdra drug substance
- Botanix Quarterly Activities Report and Appendix 4C Q4 FY26
- Appendix 4E & Annual Report for the Year Ended 30 June 2026
- S&P DJI Announces September 2026 Quarterly Rebalance
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals